Visterra, Inc. Boosts Series A to $26 Million, Adds Bill & Melinda Gates Foundation as Investor
11/9/2012 6:32:45 AM
More...
|
Visterra, Inc. Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, Viet Nam
10/29/2012 6:57:38 AM
More...
|
Visterra, Inc. Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza With VIS410, a Novel Engineered Human Antibody
9/11/2012 10:07:32 AM
More...
|